Oasmia is a pharmaceutical company based in Uppsala, Sweden, primarily focused on the development of innovative cancer treatments. The company specializes in the formulation of drugs that utilize its proprietary technology to enhance the delivery and efficacy of existing therapies. Oasmia's research and development efforts are directed towards creating new therapeutic options for patients with various types of cancer, aiming to improve treatment outcomes and quality of life.
The company has developed a portfolio of products, including both human and veterinary oncology treatments. Oasmia's lead product, Doxophos, is an injectable formulation of doxorubicin, which is designed to reduce side effects while maintaining therapeutic effectiveness. In addition to its proprietary drug formulations, Oasmia collaborates with other organizations and institutions to advance its research initiatives and expand its product offerings in the oncology sector.
Oasmia is committed to advancing cancer treatment through its innovative approaches and technologies, contributing to the broader field of oncology research and development. The company's activities are aligned with the increasing global focus on personalized medicine and targeted therapies in the fight against cancer.